CN101768202A - 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途 - Google Patents
知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途 Download PDFInfo
- Publication number
- CN101768202A CN101768202A CN200910258515A CN200910258515A CN101768202A CN 101768202 A CN101768202 A CN 101768202A CN 200910258515 A CN200910258515 A CN 200910258515A CN 200910258515 A CN200910258515 A CN 200910258515A CN 101768202 A CN101768202 A CN 101768202A
- Authority
- CN
- China
- Prior art keywords
- sarsasapogenin
- derivative
- ane marrhenae
- rhizoma ane
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 title claims abstract description 165
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 239000011347 resin Substances 0.000 claims abstract description 19
- 229920005989 resin Polymers 0.000 claims abstract description 19
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 238000001953 recrystallisation Methods 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 37
- 238000009835 boiling Methods 0.000 claims description 35
- 229960004756 ethanol Drugs 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 11
- 238000000967 suction filtration Methods 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 229930182490 saponin Natural products 0.000 claims description 10
- 150000007949 saponins Chemical class 0.000 claims description 10
- 235000017709 saponins Nutrition 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 229930013930 alkaloid Natural products 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 4
- 230000000274 adsorptive effect Effects 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010828 elution Methods 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 3
- 206010039966 Senile dementia Diseases 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 2
- 230000002745 absorbent Effects 0.000 abstract 1
- 239000002250 absorbent Substances 0.000 abstract 1
- 238000005903 acid hydrolysis reaction Methods 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- 238000003756 stirring Methods 0.000 description 23
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 230000006837 decompression Effects 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229960001701 chloroform Drugs 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003725 endotheliocyte Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 125000002346 iodo group Chemical group I* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 229930193981 timosaponin Natural products 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- WVXZNBQXPKNNSC-UHFFFAOYSA-N [C].CCCCCCCCCCCCCCCC(O)=O Chemical compound [C].CCCCCCCCCCCCCCCC(O)=O WVXZNBQXPKNNSC-UHFFFAOYSA-N 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003684 drug solvent Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- 150000008195 galaktosides Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000003350 kerosene Substances 0.000 description 2
- -1 lignanoid Natural products 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 229930002600 steroidal saponin Natural products 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000751599 Amphimedon chloros Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012809 cooling fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 229960002203 tilactase Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- BYGOPQKDHGXNCD-UHFFFAOYSA-N tripotassium;iron(3+);hexacyanide Chemical compound [K+].[K+].[K+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] BYGOPQKDHGXNCD-UHFFFAOYSA-N 0.000 description 1
- ATCZPWFDFFKCPF-UHFFFAOYSA-K trisodium;acetic acid;phosphate Chemical compound [Na+].[Na+].[Na+].CC(O)=O.[O-]P([O-])([O-])=O ATCZPWFDFFKCPF-UHFFFAOYSA-K 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Compd. Yield/% mp,Ms M/Z[M+H]+ 13C-NMR(300MHz,CDCl3)δ |
1a 80% 445 14.45,16.15,16.60,20.98,23.93,25.10,25.86,26.03,26.44,27.16,30.68×2,31.83,35.10,35.37,35.37,37.31,40.13,40.33,40.76.42.22,56.48,62.15,65.23,71.06,81.10,109.86,160.101b 60% 655 14.30,15.50,16.10,16.32,20.88,23.93,25.10,25.86,26.10,26.41,27.05,(29.00~29.58)×14,30.65,30.79,31.91,34.04,34.98,35.29,40.21,40.62,42.11,56.36,62.06,65.07,70.36,80.98,109.71,173.412a 45% 436 14.26,15.98,16.41,20.83,23.84,25.70,25.88,26.36,26.4927.01,27.73,29.88,31.66,33.46,36.44,36.81,39.79,40.1840.24,40.59,42.56,56.34,56.4462.03,65.06,80.91,109.652b 69% 481 14.53,16.24,16.68,21.13,24.24,25.38,25.98,26.16,26.6626.68,27.28,30.99,31.30,31.95,34.4435.34,37.88,40.2540.45,40.87,42.33,52.43,56.60,62.31,65.33,81.19,109.912c 30% 527 14.30,16.10,16.32,20.88,23.93,25.10,25.86,26.10,26.4127.05,29.36,30.65,30.79,31.91,34.04,34.98,35.29,40.1140.21,40.62,42.11,48.26,56.36,62.06,65.07,80.98,109.713 70% 497 14.91,15.98,16.41,20.83,23.84,25.70,25.88,26.36,26.4927.01,27.73,29.99,31.66,34.46,36.44,36.81,39.79,40.1840.24,40.59,42.56,56.34,62.03,65.06,75.44,80.91,109.654 40% 399 14.30,16.10,16.32,20.88,23.93,25.10,25.86,26.10,26.4127.05,30.65,30.79,31.91,34.04,34.98,35.29,40.11,40.2140.62,42.11,56.36,62.06,65.07,80.98,109.71,127.08,132.28 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102585150A CN101768202B (zh) | 2009-02-18 | 2009-12-12 | 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910010389.7 | 2009-02-18 | ||
CN200910010389A CN101531697A (zh) | 2009-02-18 | 2009-02-18 | 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途 |
CN2009102585150A CN101768202B (zh) | 2009-02-18 | 2009-12-12 | 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101768202A true CN101768202A (zh) | 2010-07-07 |
CN101768202B CN101768202B (zh) | 2013-10-30 |
Family
ID=42501322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102585150A Expired - Fee Related CN101768202B (zh) | 2009-02-18 | 2009-12-12 | 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101768202B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102924559A (zh) * | 2012-11-16 | 2013-02-13 | 沈阳药科大学 | 菝葜皂苷元衍生物及其制备和应用 |
CN103349724A (zh) * | 2013-08-02 | 2013-10-16 | 石任兵 | 一种知母总黄酮提取物及其同时制备知母总黄酮提取物及总皂苷提取物的方法 |
CN105193825A (zh) * | 2015-10-18 | 2015-12-30 | 苏州普罗达生物科技有限公司 | 菝葜皂苷元3位羟基甲酰酯在制备治疗宫颈炎药物中的应用 |
WO2018121770A1 (zh) * | 2016-12-30 | 2018-07-05 | 中国科学院上海药物研究所 | 一种抗抑郁化合物及其制备方法和应用 |
CN112142817A (zh) * | 2019-06-26 | 2020-12-29 | 中国科学院上海药物研究所 | 一种抗抑郁甾体化合物 |
CN113831381A (zh) * | 2020-06-24 | 2021-12-24 | 中国科学院上海药物研究所 | 一种用于治疗抑郁症的甾体化合物 |
US11319338B2 (en) * | 2012-04-03 | 2022-05-03 | Goldporp Pharma Limited | Timosaponin compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1377368A (zh) * | 1999-09-29 | 2002-10-30 | 植物药物公共有限公司 | 5-β皂草苷配基和假皂草苷配基衍生物及其在治疗痴呆中的用途 |
CN1699403A (zh) * | 2005-05-24 | 2005-11-23 | 浙江大学 | 从中药材中提取菝葜皂甙元的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0107822D0 (en) * | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
-
2009
- 2009-12-12 CN CN2009102585150A patent/CN101768202B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1377368A (zh) * | 1999-09-29 | 2002-10-30 | 植物药物公共有限公司 | 5-β皂草苷配基和假皂草苷配基衍生物及其在治疗痴呆中的用途 |
CN1699403A (zh) * | 2005-05-24 | 2005-11-23 | 浙江大学 | 从中药材中提取菝葜皂甙元的方法 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11319338B2 (en) * | 2012-04-03 | 2022-05-03 | Goldporp Pharma Limited | Timosaponin compounds |
CN102924559A (zh) * | 2012-11-16 | 2013-02-13 | 沈阳药科大学 | 菝葜皂苷元衍生物及其制备和应用 |
CN102924559B (zh) * | 2012-11-16 | 2015-10-28 | 沈阳药科大学 | 菝葜皂苷元衍生物及其制备和应用 |
CN103349724A (zh) * | 2013-08-02 | 2013-10-16 | 石任兵 | 一种知母总黄酮提取物及其同时制备知母总黄酮提取物及总皂苷提取物的方法 |
CN105193825A (zh) * | 2015-10-18 | 2015-12-30 | 苏州普罗达生物科技有限公司 | 菝葜皂苷元3位羟基甲酰酯在制备治疗宫颈炎药物中的应用 |
WO2018121770A1 (zh) * | 2016-12-30 | 2018-07-05 | 中国科学院上海药物研究所 | 一种抗抑郁化合物及其制备方法和应用 |
US11142543B2 (en) | 2016-12-30 | 2021-10-12 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Antidepressant compound and preparation method and application thereof |
CN112142817A (zh) * | 2019-06-26 | 2020-12-29 | 中国科学院上海药物研究所 | 一种抗抑郁甾体化合物 |
CN112142817B (zh) * | 2019-06-26 | 2021-10-22 | 中国科学院上海药物研究所 | 一种抗抑郁甾体化合物 |
CN113831381A (zh) * | 2020-06-24 | 2021-12-24 | 中国科学院上海药物研究所 | 一种用于治疗抑郁症的甾体化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN101768202B (zh) | 2013-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101768202B (zh) | 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途 | |
CN101035548B (zh) | 甾体皂苷药物组合物及其制备方法和应用 | |
CN101759544B (zh) | 一种新查耳酮化合物及其制备方法与其应用 | |
CN105294676B (zh) | 一种小檗碱复盐及其制备方法和用途 | |
CN104910240B (zh) | 光叶子花中三萜皂苷,以其为活性成分的降血糖药物,及其制备方法和应用 | |
CN101012230A (zh) | 斑蝥酸钠的制备工艺 | |
CN101157714A (zh) | 一种常春藤皂苷、其制备方法及其抗肿瘤用途 | |
CN108822178B (zh) | 低极性稀有人参皂苷Rg5/Rk1和Rh3/Rk2的制备方法 | |
CN101880306B (zh) | 黄腊果皂苷类成分及其制备方法和应用 | |
CN108451959A (zh) | 没食子酰葡萄糖苷类衍生物的应用及用于治疗高尿酸血症的药物组合物 | |
CN111333694A (zh) | 常春藤皂苷元衍生物在抗心肌缺氧复氧损伤药物中的应用 | |
CN102391352B (zh) | 救必应酸氨基酸衍生物及其在制备抗肿瘤的药物中的应用 | |
CN104876997A (zh) | 一种甘草次酸3-位羟基结构修饰方法 | |
CN101205249B (zh) | 从黑刺菝葜植物中制备拉肖皂苷元的方法 | |
CN102688248B (zh) | 蟾蜍甾烯类化合物在制备治疗口腔黏膜恶性肿瘤药物中的应用 | |
CN103980198B (zh) | 生物碱Casuarinine H及其在制备治疗神经退行性疾病药物中的用途 | |
CN103638031B (zh) | 化合物quinatic acid的制备方法和在制备糖苷酶抑制剂药物中的应用 | |
CN103030671A (zh) | 一种低色价芦丁的制备方法 | |
CN101851271A (zh) | 蓝萼丁素衍生物、制备方法及其用途 | |
CN106883282B (zh) | 救必应酸衍生物在制备抗肿瘤的药物中的应用 | |
CN101531697A (zh) | 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途 | |
CN101919903A (zh) | 一种冬凌草二萜提取物的制备方法 | |
CN108191945B (zh) | 日本毛连菜提取物在制备α-葡萄糖苷酶抑制剂药物中的应用 | |
CN115160396B (zh) | 从中华雪胆中提取的具有抗肠炎活性的葫芦烷型四环三萜类化合物及其制备方法与应用 | |
CN112176018B (zh) | 基于炙甘草制备甘草次酸及其衍生物的方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. Effective date: 20150909 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Song Shaojiang Inventor after: Li Minghua Inventor after: Li Mingjie Inventor before: Song Shaojiang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SONG SHAOJIANG TO: SONG SHAOJIANG LI MINGHUA LI MINGJIE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150909 Address after: 110016 Shenhe province Shenyang District Cultural Road, No. 103, No. Patentee after: Shenyang Pharmaceutical University Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Address before: 110016 Shenhe province Shenyang District Cultural Road, No. 103, No. Patentee before: Shenyang Pharmaceutical University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131030 Termination date: 20171212 |
|
CF01 | Termination of patent right due to non-payment of annual fee |